CLINICAL TRIALS PROFILE FOR ANCOBON
✉ Email this page to a colleague
All Clinical Trials for ANCOBON
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01172964 ↗ | A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas | Completed | City of Hope Medical Center | Phase 1 | 2010-08-01 | RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma. PURPOSE: This clinical trial studies genetically-modified NSCs and 5-FC in patients undergoing surgery for recurrent high-grade gliomas. |
| NCT01562132 ↗ | Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection | Terminated | Bausch Health Americas, Inc. | Phase 2 | 2013-09-01 | The purpose of this study is to determine if treatment with two medicines in combination (fluconazole and flucytosine) is safe as compared with one medicine alone (fluconazole) for the treatment of an early infection with a fungus called cryptococcus. |
| NCT01562132 ↗ | Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection | Terminated | Kenya Medical Research Institute | Phase 2 | 2013-09-01 | The purpose of this study is to determine if treatment with two medicines in combination (fluconazole and flucytosine) is safe as compared with one medicine alone (fluconazole) for the treatment of an early infection with a fungus called cryptococcus. |
| NCT01562132 ↗ | Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 2013-09-01 | The purpose of this study is to determine if treatment with two medicines in combination (fluconazole and flucytosine) is safe as compared with one medicine alone (fluconazole) for the treatment of an early infection with a fungus called cryptococcus. |
| NCT01562132 ↗ | Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection | Terminated | University of Nairobi | Phase 2 | 2013-09-01 | The purpose of this study is to determine if treatment with two medicines in combination (fluconazole and flucytosine) is safe as compared with one medicine alone (fluconazole) for the treatment of an early infection with a fungus called cryptococcus. |
| NCT01562132 ↗ | Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection | Terminated | Valeant Pharmaceuticals International, Inc. | Phase 2 | 2013-09-01 | The purpose of this study is to determine if treatment with two medicines in combination (fluconazole and flucytosine) is safe as compared with one medicine alone (fluconazole) for the treatment of an early infection with a fungus called cryptococcus. |
| NCT01562132 ↗ | Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection | Terminated | Yale University | Phase 2 | 2013-09-01 | The purpose of this study is to determine if treatment with two medicines in combination (fluconazole and flucytosine) is safe as compared with one medicine alone (fluconazole) for the treatment of an early infection with a fungus called cryptococcus. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ANCOBON
Condition Name
Clinical Trial Locations for ANCOBON
Trials by Country
Clinical Trial Progress for ANCOBON
Clinical Trial Phase
Clinical Trial Sponsors for ANCOBON
Sponsor Name
